Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATLOB: Antiviral Therapy and Long-term Outcome of Chronic Hepatitis B Patients in China (Shandong Province)
ChiCTR2100041835Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Feb 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of novaferon in Chronic Hepatitis B (CHB), sponsored by Huashan Hospital. Primary endpoint: Occurrence rate of hepatocellular carcinoma. Started Feb 2021; status: recruiting.
02
Drugs
novaferon
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2100041835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041835.